This content is in French.
Triple-negative breast cancer: can spatial and single-cell profiling predict response to immunotherapy and radiation?
21 octobre 2025
By Lila Rouland | Published on October 21, 2025 | 3 min readTriple-negative breast cancer (TNBC), lacking hormonal and HER2 receptors, represents an aggressive and heterogeneous subtype. Immune checkpoint inhibitors (ICIs), such as pembrolizumab, have recently shown therapeutic potential; however, only about 20% of metastatic patients respond to monotherapy. This highlights the urgent need for pre
Triple-negative breast cancer (TNBC), lacking hormonal and HER2 receptors, represents an aggressive and heterogeneous subtype. Immune checkpoint inhibitors (ICIs), such as pembrolizumab, have recently shown therapeutic potential; however, only about 20% of metastatic patients respond to monotherapy. This highlights the urgent need for predictive biomarkers and more effective combination strategies.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Shiao, S.L., et al. (2024). Single-cell and spatial profiling of immune trajectories under anti-PD-1 and radiotherapy in triple-negative breast cancer. Cancer Cell, 42(1), 70–84. DOI : 10.1016/j.ccell.2023.11.004
View the source
